De Novo device
UroLift System (UL400)
Neotract, Inc. · Implantable Transprostatic Tissue Retractor System (PEW, Class II) · First FDA decision Sep 13, 2013, newest Dec 20, 2019Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
De Novo pathway
Device trials
17
Naming "UroLift"
MAUDE reports
473
Brand "UroLift", since 2015
PubMed studies
222
Mentioning "UroLift"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing UroLift System (UL400)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- UroLift System (UL400)510(k)
K193269 · Decided Dec 20, 2019 · 24 days after receipt
Device type: Implantable Transprostatic Tissue Retractor System (PEW) · GI, Urology & Nephrology
- UroLift System UL400510(k)
K190377 · Decided Mar 21, 2019 · 30 days after receipt
Device type: Implantable Transprostatic Tissue Retractor System (PEW) · GI, Urology & Nephrology
K173087 · Decided Dec 28, 2017 · 90 days after receipt
Device type: Implantable Transprostatic Tissue Retractor System (PEW) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "UroLift", any status and sponsor, newest update first.
- Comparing Rezum and UroliftPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT06820606 · 120 participants (planned) · Start Jan 1, 2025 · Primary completion Sep 30, 2027
Device: Rezum; UroLift · For: Benign Prostatic Hyperplasia
Sites: Hong Kong, Hong Kong
Northwell HealthAcademic, hospital or other
NCT05148156 · 20 participants (planned) · Start Feb 11, 2026 · Primary completion Sep 2027
Device: Urolift · For: Benign Prostatic Hyperplasia
Sites: Syosset, New York
- Post-Market Study to Assess iTind Safety in Comparison to UroLiftPivotal-lookingRecruiting
Olympus Corporation of the AmericasPublic (7733.T)
NCT04757116 · 256 participants (planned) · Start Sep 26, 2022 · Primary completion Jul 15, 2027
Device: iTind · For: Benign Prostatic Hyperplasia (BPH)
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 19 sites in all
14 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "UroLift", and for the whole product code for context.
This brand
473 reports: 227 malfunction, 234 injury, 12 death
Whole product code PEW
498 reports: 250 malfunction, 236 injury, 12 death
Newest reports for this brand
- UroLift UL2 ATC Implant CartridgeMalfunction
3015181082-2026-00083 · Received Oct 9, 2026 · Event dated Aug 26, 2026
Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Device problem as coded: Device Handling Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- UroLift 2 Implant CartridgeMalfunction
3015181082-2026-00085 · Received Oct 8, 2026 · Event dated Sep 11, 2026
Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- UroLift 2 Implant CartridgeMalfunction
3015181082-2026-00084 · Received Oct 8, 2026 · Event dated Sep 11, 2026
Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1502-2022 · Started Jun 24, 2022 · Posted by FDA Aug 5, 2022
Reason given: There is the potential that during implant deployment, the device may not properly deliver a implant.
Cause as FDA categorized it: Under Investigation by firm · Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Z-0598-2019 · Started Jul 6, 2018
Reason given: Upon implant deployment, the Capsular Tab may not be delivered as the needle is retracted. In this failure mode, the needle is deployed into the prostate and retracted, leaving no implant behind. Failure to deliver a capsular tab may result in a delay in completing a treatment or an inability to complete a treatment...
Cause as FDA categorized it: Finished device change control · Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Published research
The most relevant PubMed records for "UroLift"[tiab]. The summary above synthesizes these.
- Recent advances in UroLift: A comprehensive overview.
Denisenko A, Somani B, Agrawal V · Turk J Urol · 2022
- The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction.
Roehrborn CG, Chin PT, Woo HH · Prostate Cancer Prostatic Dis · 2022Research Support, Non-U.S. Gov't
- Prostatic urethral lift (UroLift): a real-world analysis of outcomes using hospital episodes statistics.
Page T, Veeratterapillay R, Keltie K, et al. · BMC Urol · 2021Observational Study
- Urolift - minimally invasive surgical BPH management.
Pushkaran A, Stainer V, Muir G, et al. · Expert Rev Med Devices · 2017Review
- UroLift, Rezūm, and iTind for Benign Prostatic Hyperplasia.
Cheema AS, Long BG, Moore KE, et al. · Urol Clin North Am · 2025Review
- Does the UroLift® device change things?
Gilling PJ · BJU Int · 2017Editorial, Comment
- Office-Based Procedures for BPH.
Gao B, Lu S, Bhojani N, et al. · Curr Urol Rep · 2021Review
- UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update.
Knight L, Dale M, Cleves A, et al. · Appl Health Econ Health Policy · 2022Review
- UroLift to preserve seminal parameters in young male with LUTS from BPH.
Annese P, d'Altilia N, Falagario UG, et al. · World J Urol · 2024
- The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance.
Ray A, Morgan H, Wilkes A, et al. · Appl Health Econ Health Policy · 2016Review
- UroLift: a new minimally-invasive treatment for benign prostatic hyperplasia.
Jones P, Rai BP, Aboumarzouk O, et al. · Ther Adv Urol · 2016Review
- Pelvic Hematoma After UroLift: A Case Report and Literature Review.
Rodríguez-Fernández LF, Bernaschina-Bobadilla CP · Cureus · 2023Case Reports
Other devices of this type
Also filed under product code PEW.
- NeoTract UroLift System UL500Neotract, Inc. · 510(k) 2016
- UroLift 2 ATC Advanced Tissue Control SystemNeotract, Inc. · 510(k) 2023
- UroLift 2 System (formerly UL500)Neotract, Inc. · 510(k) 2020
- UroLift Advanced Tissue Control (ATC) SystemNeotract, Inc. · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.